The Global HIV diagnostics market size is expected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the development in technology for diagnostic tests, projected development and commercialization of novel, authorization of regulatory bodies for tests such as p24 antigen, EID, POC, and rapid CD4 test.
The human immunodeficiency virus (HIV) is a retrovirus, which is responsible for causing the acquired immunodeficiency syndrome or AIDS. It affects cells of immunity system and weaken immunity system. Some tests are performed in urine samples, saliva, or serum for the diagnosis of HIV. These tests help to detect RNA, antibodies, and antigens. The rising demand for this process is due to appropriate counselling, growing awareness about HIV, and confidentiality of the test. According to UNAIDS, globally around 38 million people were infected by HIV, 1.8 million people were newly affected with HIV, and approximately 770050 people died due to AIDS related illnesses by the end of 2018.
There are some limitations for laboratory based testing such as less trained clinical technicians and insufficient testing laboratories. These limitations are projected to propel the development and easy implementation of point of care (POC) and rapid tests. In current scenario, POC and rapid test are under various clinical development and investigation in pipelined products of key market players. Favorable regulatory authorization and growing number of product offerings from key players are anticipated to boost the market growth during the forecast period.
HIV Diagnostics Market Trends, Drivers, Restraints, and Opportunities
- Rising number of blood donation and blood transfusions is anticipated to boost the market expansion during the forecast period.
- Increasing occurrence of HIV/AIDS globally and government initiatives are projected to drive the market growth during the forecast period.
- Advantages given by POC instruments and kits are another major factors to propel the market growth.
- High price of nucleic acid testing (NAT) and lack of mandatory testing for NAT are key challenges expected to impede the market growth.
- Growing use of home access kits and development of innovative HIV testing devices are projected to offer lucrative opportunities for the market growth.
Scope of the HIV Diagnostics Market Report
The report on the global HIV diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
HIV Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Products (Antibody Tests, Viral Identification Assays, CD4 Testing, Viral Load Testing, and Early Infant Diagnosis)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Alere Inc., Abbott Healthcare, Abbvie Inc., Brsitol-Myers Squibb, Janssen Therapeutics, Gilead Sciences, Merck & Co. Inc., VIIV Healthcare, BD Biosciences, Beckman Coulter, Partec, Sysmex, Apogee Flow Systems, PointCare Technologies Inc., Zyomyx Inc., Mylan Inc., Roche Diagnostics, Siemens Healthcare, Qiagen, and bioMerieux
|
HIV Diagnostics Market Segment Insights
Antibody tests segment is projected to hold a key market share
Based on products, the global HIV diagnostics market is segmented into antibody tests, viral identification assays, CD4 testing, viral load testing, and early infant diagnosis (EID). The antibody tests segment is projected to hold a key market share during the forecast period owing to availability of several numbers of antibody tests. The tests can be subdivided into HIV-1 screening, 1 confirmatory, and 2 & Group O tests. Additionally, these tests include several tests such as radioimmuno-precipitation assay for confirmation of disease, western blot, modern 3rd and 4th generation ELISA tests, rapid agglutination for HIV-1 screening, and line immunoassays for disease confirmation, subtyping, and screening. Confirmatory tests and diagnostic screening for HIV-1, 2, and Group O prevalence testing are included in the HIV diagnostics market. Major objective of these tests is to differentiate and screen numerous groups and subtypes of HIV.
On the other hand, the EID segment is anticipated to account for a large market share in the coming years owing to wide adoption of the diagnosis for children. This is separately conducted because children who are under the age of 18 months have antibodies present from maternal blood.
North America is expected to dominate the market
On the basis of regions, the HIV diagnostics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing expenditure on R&D sector, reimbursement policies, and technologically advanced healthcare framework. Moreover, development in technology for rapid and portable diagnostic tests, presence of major market players, and high occurrence of HIV/AIDS in this region are key factors responsible for the regional market growth. On the other hand, the market of Asia-Pacific is projected to grow at a faster rate during the forecast period because of the rising HIV cases and several government policies for the development of healthcare infrastructure from major countries such as India and China.
Segments
Segments Covered in the Report
The global HIV diagnostics market has been segmented on the basis of
Products
- Antibody Tests
- Viral Identification Assays
- CD4 Testing
- Viral Load Testing
- Early Infant Diagnosis (EID)
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Alere Inc.
- Abbott Healthcare
- Abbvie Inc.
- Brsitol-Myers Squibb
- Janssen Therapeutics
- Gilead Sciences
- Merck & Co. Inc.
- VIIV Healthcare
- BD Biosciences
- Beckman Coulter
- Partec
- Sysmex
- Apogee Flow Systems
- PointCare Technologies Inc.
- Zyomyx Inc.
- Mylan Inc.
- Roche Diagnostics
- Siemens Healthcare
- Qiagen
- bioMerieux
Competitive Landscape
Key players competing in the global HIV diagnostics market include Alere Inc., Abbott Healthcare, Abbvie Inc., Brsitol-Myers Squibb, Janssen Therapeutics, Gilead Sciences, Merck & Co. Inc., VIIV Healthcare, BD Biosciences, Beckman Coulter, Partec, Sysmex, Apogee Flow Systems, PointCare Technologies Inc., Zyomyx Inc., Mylan Inc., Roche Diagnostics, Siemens Healthcare, Qiagen, and bioMerieux.
Key players of the market are majorly focuses on clinical R&D of viral load testing, CD4, and p24antigen tests for reducing the complexity and rising accessibility of testing facilities. Major market players are increasingly adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
